GSK3B and Bloom syndrome: In order to investigate how galectin-3 activates ECs to regulate vascular remodeling in BLM-induced IPF, we examined the protein expression of ECs and mesenchymal biomarkers along with regulators of the AKT/GSK3β/β-catenin singling pathway after treatment with the galectin-3 antagonist GB1107 or vehicle (DMSO).